Market Research Blog – Page 1295 – New Product Development

PCSK9 Inhibitor Market to Surge with 21.5% Growth, Projected to Reach USD 15,140.3 Million by 2034

The global PCSK9 inhibitor market is set to experience substantial growth, with an estimated market size of USD 2,733.7 million in 2024, reflecting a year-over-year growth of 21.5%. The market is projected to expand at a robust compound annual growth rate (CAGR) of 18.7% throughout the forecast period, with total sales anticipated to reach approximately USD 15,140.3 million by 2034.

The market’s impressive growth trajectory is driven by increasing adoption of PCSK9 inhibitors for managing high cholesterol levels and advancements in cardiovascular disease treatment. Among the various segments, evolocumab is expected to dominate the PCSK9 inhibitor industry, holding a substantial value share of 71.3% in 2024.

Additionally, the inclisiran segment is forecasted to exhibit remarkable growth, with sales expanding at a staggering CAGR of 31.3% during the assessment period. This rapid expansion is attributed to the innovative nature of inclisiran and its growing acceptance in clinical settings.

PCSK9 inhibitors, a class of drugs designed to lower LDL cholesterol levels in patients who are at high risk of cardiovascular events, continue to gain traction in the healthcare industry due to their efficacy and potential to address unmet needs in cardiovascular care.

According to research, PCSK9 Inhibitors are effective at lowering cholesterol. PCSK9 Inhibitors are administered once or twice a month through injection under the skin, self-administration, or medical representation. As a result, the PCSK9 Inhibitors Market is expected to grow and increase significantly throughout the forecast period. The worldwide PCSK9 Inhibitors Market is expected to thrive in the future, with a substantially higher CAGR.

During the projected period, Europe is estimated to have the highest global PCSK9 Inhibitors Market share. This is owing to increased spending and better healthcare infrastructure in nations such as Germany, Italy, and Spain, which are the region’s major contributors to growth.

Key Takeaways from the Market Study

FMI projects the global PCSK9 Inhibitors market to expand at a 15.8% value CAGR by 2033
The global PCSK9 Inhibitors market is estimated at a market value of US$ 3 Billion
The global PCSK9 Inhibitors market is expected to garner a market value of US$ 13 Billion
Asia Pacific is expected to grow at a CAGR of 15% in the assessment period 2023-2033.
North America is expected to grow at a CAGR of 15.7% in the assessment period 2023-2033.
Europe is expected to grow at a CAGR of 15.3% in the assessment period 2023-2033.
The Repatha segment is expected to hold the largest market share for PCSK9 Inhibitors in the forecast period 2023-2033

“Asia Pacific is expected to have a significant market share. This is due to increased healthcare awareness, research activity, and government initiatives in the healthcare industry to create jobs in the region,” says an analyst at FMI.

Market Competition

New product registrations for early diagnosis, strategic alliances for mergers, acquisitions, marketing, a large distribution channel, and significant R&D investment are some of the primary strategies employed by notable organisations operating in the PCSK9 inhibitors Market. The top players in the PCSK9 inhibitors industry have been identified and characterised for their distinct business features. Key players in the PCSK9 Inhibitors market are Amgen, Eli Lilly, Sanofi, Pfizer, Novartis, Roche, Merck, Alnylam, AstraZeneca and Affiris.

Recent Developments:

In December 2022, the boards of directors of Horizon Therapeutics plc and Amgen Inc., announced that they have agreed on the terms of a cash offer for the Company by Pillartree Limited (“Acquirer Sub”), a newly formed private limited company wholly owned by Amgen, which is unanimously recommended by the Company Board and under which Acquirer Sub will acquire the entirety of the Company’s issued and to be issued ordinary share capital.
In December 2022, Eli Lilly and Company announced that its purchase of Akouos, Inc. was completed successfully. The purchase broadens Lilly’s genetic medicines efforts to include Akouos’ portfolio of potential first-in-class adeno-associated viral gene treatments for the treatment of inner ear diseases such as sensorineural hearing loss.

More Insights Available

Future Market Insights, in its new offering, presents an unbiased analysis of the global PCSK9 Inhibitors market, presenting historical analysis from 2018 to 2022 and forecast statistics for the period of 2023-2033.

The study reveals essential insights on the basis of type (repatha, praluent, bococizumab and others), and application (clinical application, drug development and others), across five major regions (North America, Latin America, Europe, Asia Pacific and Middle East & Africa).

Key Players:

Amgen Plc.
Eli Lilly & Co.
Sanofi S.A
Pfizer Inc.
Novartis AG
Roche Diagnostics
Merck & Co. KGaA
Alnylam
AstraZeneca
Affiris

A Old Full Report Analysis Click Here

Key Segments Profiled in the PCSK9 Inhibitors Industry Survey

By Type:

Repatha
Praluent
Bococizumab
Others

By Application:

Clinical Application
Drug Development
Others

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Oncolytic Virus Cancer Therapy Market Poised for Rapid Growth, Projected to Reach USD 250 Million by 2033 at a 27% of CAGR

The global oncolytic virus cancer therapy market is set for exceptional growth, with an anticipated valuation of USD 22.86 million in 2023. According to recent market projections, the sector is expected to expand at a remarkable compound annual growth rate (CAGR) of 27% from 2023 to 2033, reaching an estimated market value of USD 250 million by the end of the forecast period.

This significant growth underscores the increasing interest and investment in innovative cancer therapies. Oncolytic virus therapy, which leverages genetically modified viruses to target and destroy cancer cells, is gaining traction due to its potential to revolutionize cancer treatment and improve patient outcomes.

Oncolytic virus cancer therapy, an innovative approach that leverages genetically modified viruses to selectively target and destroy cancer cells while sparing healthy tissues, is gaining significant traction in the oncology field. The substantial growth forecast underscores the increasing adoption of this therapy as a promising treatment option for various types of cancer.

Government agencies in developed and developing countries are conducting education programs to encourage people to seek early cancer diagnosis, which is expected to increase the number of patients who will be eligible for numerous new therapies.

Due to a significant increase in the number of companies that produce cancer medications, the Asia Pacific region will have the highest ownership stake in the oncolytic virus cancer market. The oncolytic virus therapy market is growing in revenue and earnings as countries such as China and Japan introduce breakthroughs into the market.

Because of the region’s high incidence of cancer, particularly melanoma cancer, North America is expected to be the most valuable region for the global oncolytic virus cancer market. Increased cancer incidences around the world are creating a positive outlook for the market. In line with this, the therapy’s widespread use in the treatment of a wide range of melanomas, including haematological malignancies, lymphoma, leukaemia, and myeloma, is boosting overall growth.

Key Takeaways from the Market Study

The number of articles on oncolytic virus therapy studies has increased by 395% in the last decade.
In 2022, Japan’s total oncolytic virus cancer market share was US$ 2 Million, and it is expected to rise during the study period.
North America is expected to grow at the fastest rate during the forecast period, with a CAGR of 29.5%.
In the United States in 2021, the market value for oncolytic virus therapies was US$ 8.5 Million
The global oncolytic virus cancer market is expected to be worth US$ 250 Million.

“As oncology takes a turn for the better, healthcare practitioners are implementing highly advanced ways of diagnosing and treating some of the most debilitating cancers, paving way for enhanced adoption of oncolytic virus cancer therapies,” remarks an FMI analyst.

Market Competition

Key players in the Oncolytic Virus Cancer market are Oncolytics Biotech Inc, Amgen Inc., Sorrento Therapeutics, Transgene SA, Daiichi Sankyo Company, Shanghai Sunway Biotech Co, Ltd, Takara Bio Inc., PsiOxus Therapeutics, SillaJen Inc., ViroCure.

Amgen, based in the United States, agreed to pay $3.7 billion for the biopharma firm ChemoCentryx in August 2022. As a result of this strategic initiative, Amgen will provide access to Tavneos, the company’s critical therapy that has received therapy confirmation in the EU and Japan. Amgen will be able to expand its reach and develop in regions such as Europe and Asia Pacific as a result of this acquisition.
In April 2021, Bristol Myers Squibb and PsiOxus Therapeutics enlarged their partnership to investigate PsiOxus Therapeutics’ cancer-killing virus. According to the contract, the collaboration will incorporate Bristol’s checkpoint reagent Opdivo and novel resource NG-641 in various types of tumors. PsiOxus’ oncolytic virus ‘enadenotucirev’ is the basis for NG-641.

A Old Full Report Analysis Click Here

Key Segments Profiled in the Oncolytic Virus Cancer Therapy Market Industry Survey

By Virus Type:

Genetically Engineered Oncolytic Viruses
- Herpes Simplex Virus
- Adenovirus
- Vaccinia Virus
Oncolytic Wild-type Viruses
- Reovirus
- Newcastle Disease Virus
- Vesicular Stomatitis Virus

By Application:

Solid Tumor
- Breast Cancer
- Prostate Cancer
- Lung Cancer
- Glioblastoma
Melanoma
- Hematological Malignancies
- Lymphoma
- Leukemia
- Myeloma

By End Use:

Hospitals
Specialty Clinics
Cancer Research Institutes

About Future Market Insights (FMI)

Contact Us:

Global Chronic Wound Care Market Forecasted to Reach USD 25,042.5 Million by 2033, with a CAGR of 3.8%

The global chronic wound care market is poised for significant growth, with expectations to rise at a compound annual growth rate (CAGR) of 3.8% from 2023 to 2033. The market, valued at USD 17,272.4 million in 2023, is projected to increase to approximately USD 25,042.5 million by 2033.

In 2022, the chronic wound care market was valued at USD 16,689.3 million and is anticipated to exhibit a year-over-year growth of 3.5% in 2023. This upward trend reflects the growing demand for advanced wound care solutions and innovations in treatment methods.

Additionally, Indian Institute of Science researchers have created bandages that include magnetic nanofibers that can cure skin cancer non-invasively. Researchers at IISc have come up with a bandage that’s fabricated by electrospinning using a unique blend of nanoparticles. It has been demonstrated that real-time monitoring of wound parameters at the site of the wound is crucial for effective wound care using various sensing techniques, including physical and chemical sensors.

The development of technologies to monitor a variety of biomarkers affecting wound healing, such as temperature, pressure, pH, and infection status, has been a focus of considerable effort in recent years. On-demand and local drug delivery have been developed as advanced wound therapies to assist in the diagnosis and treatment of wounds.

The advancement of technology and innovative 3D techniques, along with trackers and apps, will allow consumers to monitor the healing process of their finger wounds. For instance, Heriot-Watt University researchers developed tiny sensors that track wound healing and speed using a bandage under a bandage. There have been many studies on wound biology, but little is known about the physicality’s that contribute to wound healing, especially at the microscale, where advancement occurs at sub-hair widths. Crichton writes that few studies have actually been conducted on wounds.

Key Takeaways from the Market Study 

The global market size for chronic wound care is estimated to reach US$ 15.98 Billion by 2023.
According to the forecast, the market is expected to grow by 7% between 2023 and 2033, reaching a total of US$ 31.46 billion by 2033.
Across all wound dressing categories in 2023, advanced wound dressings accounted for 54% of the total market value.
Chronic wound care in North America expanded with a market share of 33% in 2022.
According to forecasts, by 2023 the diabetic ulcer market will account for 38% of the total market value.

“As diabetic ulcers become more prevalent and new drugs and devices are approved, artificial intelligence and technology are expected to play a significant role in growing sensor-based bandages.” comments a Future Market Insights analyst.

Competitive Landscape 

Research and the development of innovative diagnostic techniques are expected to be the focus of many companies in the near future, resulting in the expansion of their product lines, the acquisition of other companies, and the merger of their businesses.

Healthium Medtech, based in Bengaluru, has introduced its new wound dressing portfolio Theruptor Novo to manage chronic wound care such as diabetic foot ulcers and leg ulcers. Healthium expands its portfolio of advanced wound dressing products with Theruptor Novo. Approximately 25% of diabetics will develop a foot ulcer during their lifetime. As a result of complications caused by untreated diabetic foot ulcers, almost 1 lakh amputations have been registered in India today. In addition to being painful and expensive, foot ulcers require a lot of treatment.
In an era when complex chronic wound care are on the rise, while access to wound care nurse specialists is becoming more challenging, HARTMAN USA and Corstrata announce their partnership to support home health and other in-home providers. Clinical expertise and evidence-based treatment protocols are essential to integrate advanced wound dressings with a successful wound care program. BerryDunn’s National Healthcare at Home Best Practices and Future Insights Study, published in recent months by top-50 accounting firm BerryDunn, indicates that wound-certified specialists are on staff at all of the top 10% of home health agencies with positive financial surpluses.

Key Companies Profiled:

Paracrine, Inc.
Oneness Biotech
Biotissue
Polarity TE
MediWound
Anterogen Co., Ltd.
TR Therapeutics
RHEACELL GmbH & Co.KG
Smith & Nephew
Kaken Pharmaceutical

Non-healing wounds involves a multi-disciplinary approach that may include wound debridement (removing dead or infected tissue), wound dressings, offloading (reducing pressure on the wound), and the use of advanced wound care products like growth factors or skin substitutes.

A Old Full Report Analysis Click Here

Key Segments Profiled in the Chronic Wound Care Market Industry Survey

Type:

Diabetic Ulcers
Pressure Ulcers
Venous Ulcers
Other Chronic Wounds

Product:

Advanced Wound Dressings
Wound Care Therapy
Active Therapy
Others

End User:

Hospital and Wound Care Centers
Homecare Settings
Others

About Future Market Insights (FMI)

Contact Us:

Global HER2-Positive Gastric Cancer Market Set for Growth, Projected to Reach USD 1,779.8 Million by 2033 at a 3.5% of CAGR

The global HER2-positive gastric cancer market is on a promising growth trajectory, with a current valuation of USD 1,261.8 million in 2023. According to the latest market analysis, this sector is expected to expand at a compound annual growth rate (CAGR) of 3.5% over the next decade. By 2033, the market is projected to reach approximately USD 1,779.8 million.

This positive outlook is driven by significant advancements in healthcare technology and an increasing focus on targeted therapies. The development of innovative treatment options and improved diagnostic tools are expected to contribute to the market’s expansion.

This growth is largely driven by ongoing technological advancements in the healthcare sector, which are enhancing treatment options and improving patient outcomes for those diagnosed with HER2-positive gastric cancer. As research and development in targeted therapies continue to advance, the market is poised for sustained growth over the next decade.

The anticipated expansion reflects the critical importance of innovation in the treatment of gastric cancer, particularly for patients with HER2-positive tumors, who require specialized and effective therapeutic approaches. The market’s growth underscores the healthcare industry’s commitment to improving cancer care and addressing the needs of patients worldwide.

For instance, in January 2021, the U.S. FDA approved Enhertu, an antibody-drug conjugate product for treating HER-2-positive metastatic gastric cancers. Additionally, the increasing number of special designations for drugs in the pipeline is also expected to fuel the growth of the market.

North America dominates the HER 2 positive gastric cancer market due to the presence of key market players’ presence, along with recent product launches and established healthcare infrastructure, which will accelerate the market’s growth in the region. The significant R&D investments in Europe abode well for market growth.

Key Takeaways from the Market Study

As of 2023, the HER2 positive gastric cancer market was valued at US$ 1261.8 Million
From 2023 to 2033, the HER2 positive gastric cancer industry is poised to grow at an 3.5% CAGR
By 2033, the HER2 positive gastric cancer market is slated to reach a valuation of US$ 1779.8Million
Based on therapy, the targeted therapy segment dominated the global market in 2023 with a revenue share of over 55.4%.
China is poised to yield a CAGR of 3.2% with respect HER2 positive gastric cancer in 2033

“Technological advancement in healthcare and increase in the prevalence of gastric cancer is expected to radically transform the HER 2 positive gastric cancer market in the coming years,” comments an analyst at FMI.

Competitive Landscape

AstraZeneca
Bayer
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd
Hutchison Medipharma
LintonPharm
Shanghai Henlius Biotech
Sanofi
Pfizer
Novartis AG

Manufacturers and players functional in the global HER 2 positive gastric cancer market are adopting various corporate growth strategies such as new product launches, mergers and acquisitions, and geographical expansion, among others.

In September 2022 -Shanghai Henlius Biotech, Inc announced a phase 1 clinical trial of the company’s HLX22, an anti-human epidermal growth factor receptor-2 (HER2) humanised monoclonal antibody(mAb) injection, has been completed in patients with HER2 overexpressing advanced solid tumours. The results of this study demonstrated the good safety and tolerability of HLX22.
In January 2022 — LintonPharm Co., Ltd., a China-based biopharmaceutical company focusing on the development of T cell engaging bispecific antibodies for cancer immunotherapy, announces that it has completed the enrollment of stage 1 of the global phase III trial (clinicaltrials.gov: NCT04222114). This trial evaluates the safety and efficacy of Catumaxomab, a bispecific monoclonal antibody, in adult patients with advanced Gastric Cancer with Peritoneal Carcinomatosis (GCPC).

A Old Full Report Analysis Click Here

Key Segments Covered in HER2 Positive Gastric Cancer Industry Survey

HER2 Positive Gastric Cancer Market by Therapy:

Chemotherapy
Immunotherapy
Radiation Therapy
Targeted Therapy

HER2 Positive Gastric Cancer Market by Stage:

Stage I
Stage II
Stage III
Stage IV

HER2 Positive Gastric Cancer Market by End-User:

Ambulatory surgery centres,
Hospitals and Specialty clinics
Others

About Future Market Insights (FMI)

Contact Us:

Parkinson’s Disease Therapeutic Market Poised for Steady Growth, Projected to Reach USD 6.7 Billion by 2034 at a 5.1% of CAGR

The Parkinson’s Disease Therapeutic market is on an upward trajectory, with significant growth anticipated in the coming decade. According to the latest market analysis, the market is expected to achieve a valuation of USD 4.3 billion in 2024 and is projected to expand to approximately USD 6.7 billion by 2034. This growth represents a compound annual growth rate (CAGR) of 5.1% over the next ten years.

The steady increase in market size reflects the growing demand for advanced therapeutic solutions and ongoing advancements in treatment options for Parkinson’s disease. As the global population ages and awareness of the disease increases, the market is set to experience robust expansion.

The steady increase in market size reflects the growing emphasis on developing innovative treatments and therapies for Parkinson’s disease. As research advances and new therapeutic options emerge, the market is expected to benefit from heightened investment in medical research and a stronger focus on addressing the needs of patients living with this neurodegenerative condition.

The market’s expansion underscores the ongoing commitment to improving patient outcomes through advanced therapies and enhanced treatment options. With continued innovation and a dedicated effort to address the challenges of Parkinson’s disease, the therapeutic market is poised for continued progress and growth.

According to the Parkinson’s Foundation, males are more likely than women to have Parkinson’s disease. Men were discovered to have a higher occurrence, and their risk was shown to be around 1.5 times higher than that of women. Most often, those over 60 are affected by it. A number of the symptoms of Parkinson’s disease can be alleviated with medication and other therapy methods including exercise. Drugs including safinamide, levodopa, benztropine, pramipexole, and selegiline are important therapy options for Parkinson’s disease patients.

Increasing pharmacological approvals for the Parkinson’s disease treatment are anticipated to stimulate market expansion throughout the anticipated time frame. For instance, the Japanese pharmaceutical and biotechnology company Kyowa Kirin Co., Ltd. reported in August 2019 that the NOURIANZ medication has received FDA clearance in the United States (istradefylline). It is used as an additional therapy to levodopa/carbidopa in adult patients with Parkinson’s disease who are having ‘OFF’ episodes (PD).

When a patient’s medications are not functioning effectively, it can lead to an increase in Parkinson’s disease (PD) symptoms including tremor and walking problems, which is known as an “off episode.” In the US, NOURIANZ (istradefylline), an antagonist of the adenosine A2A receptor, is used for Parkinson’s disease. The medication offers patients with Parkinson’s disease a brand-new non-dopaminergic once-daily oral treatment alternative. Such developments are expected to spur the global growth in the Parkinson’s disease market from 2023-2033.

Key Takeaways from the Market Study

The global Parkinson’s disease market is currently worth more than US$ 4.82 Billion.
In 2023, the Carbidopa-levodopa segment by drug class type is expected to take the dominant market share of 32%.
In 2023, considering the age type, the adult segment is predicted to gain a 21% market share.
The North American market for Parkinson’s disease is predicted to grow with a steady CAGR of 12.5% from 2023-2033.
The APAC for Parkinson’s disease is expected to grow with a steady CAGR of 12% during 2023-2033.

“The market is anticipated to expand as more drugs are approved for the treatment of Parkinson’s disease and as there is a robust pipeline of novel medications being developed for the condition.” comments a Future Market Insights analyst.

Competitive Landscape

Some of the top players in the global Parkison’s disease market are:

Sunovion Pharmaceuticals
Adamas Pharmaceuticals
Neurocrine Biosciences
Supernus Pharmaceuticals
Alectos Therapeutics
Kyowa Kirin
AbbVie
Integrative Research Laboratories AB
Annovis Bio Inc.
Cerevel Therapeutics
Biogen Inc.
Amneal Pharmaceuticals

Some of the recent developments in this domain are:

Biogen Inc. and Alectos Therapeutics signed an agreement in June 2022 to develop and market GBA2 inhibitors (AL01811), a possible therapy for Parkinson’s disease patients. This agreement grants Biogen worldwide rights to research, manufacture, and commercialize AL01811. They think they will be well-suited to assist bring AL01811 to patients who need it by combining Alectos’ experience in small-molecule therapies with Biogen’s worldwide development expertise in Parkinson’s disease. They are indeed energized by the prospect of using Biogen’s commercial skills to raise the standard of treatment in Parkinson’s disease as well as movement disorders in general.

More Valuable Insights Available

Future Market Insights, in its new offering, presents an unbiased analysis of the Parkinson’s disease market, presenting historical demand data (2018-2022) and forecast statistics from 2023 to 2033.

The study divulges essential insights on the market based on the parkinson’s disease market by type (juvenile parkinson disease, young-onset parkinson’s disease, idiopathic parkinson disease), by age (adult and pediatric), by diagnosis (CT Scan, MRI Scan, DaTSCAN-SPECT scan, PET Scan), by drug class (carbidopa-levodopa, carbidopa-levodopa infusion, dopamine agonists, monoamine oxidase b inhibitors, catechol o-methyltransferase inhibitors, anticholinergics, amantadine) and regions.

A Old Full Report Analysis Click Here

Key Segments Profiled in the Amyotrophic Lateral Sclerosis Industry Survey

Treatment:

Medication
Stem Cell Therapy
Others

Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
Others

Region:

North America
Latin America
Europe
Asia Pacific
MEA

About Future Market Insights (FMI)

Contact Us:

Global Air Ambulance Services Market to Reach USD 19.5 Billion by 2032, Growing at 12.3% CAGR

A newly released market analysis report by Future Market Insights reveals that the global Air Ambulance Services Market was valued at USD 5.5 billion in 2021. The market is expected to grow at a robust compound annual growth rate (CAGR) of 12.3% between 2022 and 2032, with the total market valuation projected to reach USD 19.5 billion by 2032.

The rotary-wing air ambulance service segment is expected to lead the market in terms of revenue generation, forecasted to grow at a CAGR of more than 12.4% over the same period. Rotary-wing air ambulances are increasingly being utilized due to their ability to access remote or difficult-to-reach locations and provide critical care during patient transport.

The anticipated expansion of the air ambulance services market is driven by advancements in medical technology, increased investments in emergency healthcare infrastructure, and the rising need for timely medical intervention in critical situations. As the healthcare sector continues to prioritize rapid response capabilities, the market for air ambulance services is set to grow significantly.

FMI, in its business report, elaborates the historical and current scenario of the global Air Ambulance Services Market in terms of production, consumption, volume, and value. The report scrutinizes the market into various segments, regions and players on the basis of demand pattern and growth prospects.

Crucial information and forecast statistics covered in the Air Ambulance Services market report will arm both existing and emerging market players with necessary insights to craft long-term strategies as well as maintain business continuity during a crisis such as the ongoing COVID-19 pandemic.

COVID-19 Impact Analysis on Air Ambulance Services Market

The recent outbreak of the COVID-19 has turned the spotlight on the healthcare industry, and subsequently impacted the Air Ambulance Services market. Severe shortages of critical medical supplies and a rapid rise in number of COVID-19 cases have resulted into a revolution rather than evolution in the healthcare ecosystems. Consequently, the impact is noticeable in the Air Ambulance Services market.

Following government’s measures, particularly social distancing norms and stay-at-home orders, doctors are delaying or postponing elective surgeries unless critical to prevent the spread of the virus to individuals with comorbidities or chronic conditions. Additionally, movement restrictions and supply chain disruptions have created a logistical nightmare for market players, leading to severe product shortages in the global marketplace.

The FMI’s report includes an interesting chapter on preliminary impact of the COVID-19 on the Air Ambulance Services market. This allows both leading and emerging market players to understand the market scenario during a crisis and aids them in making sound decisions to gain a distinct competitive edge.

A Old Full Report Analysis Click Here

Air Ambulance Services Market: Segmentation

Valuable information covered in the FMI’s Air Ambulance Services market report has been segregated into key segments and sub-segments.

By Type:

Rotary-wing
Fixed-wing

By Service Model:

Hospital-based
Community-based

Air Ambulance Services Market: Competition Analysis

The FMI’s study presents a comprehensive analysis of global, regional, and country-level players active in the Air Ambulance Services market. Competitive information detailed in the Air Ambulance Services market report has been based on innovative product launches, distribution channels, local networks, industrial penetration, production methods, and revenue generation of each market player. Furthermore, growth strategies and mergers & acquisitions (M&A) activities associated with the players are enclosed in the Air Ambulance Services market report.

Key players covered in the report include:

AMR, PHI Air Medical, Babcock Scandinavian Air Ambulance, Express Air Medical Transport, REVA, Inc., Lifeguard Ambulance Service LLC, Acadian Ambulance, IAS Medical, Ltd., and American Air Ambulance

About Future Market Insights (FMI)

Contact Us:

Texturized Vegetable Protein Market Set to Surge with Rapid Growth and Record CAGR by 2031

Picture background — Texturized Vegetable Protein Market

The Texturized Vegetable Protein market is a rapidly growing segment of the food industry that offers a plant-based alternative to meat-based protein sources. Texturized Vegetable Protein, also known as textured soy protein or textured plant protein, is derived from soybeans and other plant-based ingredients. It is widely used as a meat substitute due to its high protein content, texture, and versatility in various food applications.

The global TVP market has witnessed significant growth in recent years, driven by several factors. Firstly, the increasing consumer demand for plant-based and vegetarian/vegan diets has propelled the market forward. As people become more health-conscious and environmentally aware, they are seeking alternatives to traditional meat products. TVP provides a sustainable and ethical option by reducing reliance on animal protein.

The rising awareness among consumers about a multitude of health benefits of plant-based sources of protein has been aiding the market for texturized vegetable protein. Future Market Insights (FMI) in a new study has forecast the market to exhibit 6.5% CAGR by 2031. Growth forecasts continue to remain positive for the market, thanks to increasing number of vegetarian population worldwide.

Continuously increasing demand for food & beverage products which provide nutritional benefits with sensory taste is one of the major factor driving the demand for texturized vegetable protein. Due to increasing awareness regarding animal cruelty and environmental damages caused by excessive consumption of might the demand for texturized vegetable protein is expected to increase.

These protein sources also contain lower amount of saturated fat and cholesterol as compared to meat products hence are considered to have more health benefits. Among products available, the demand for soy protein is expected to be the highest. As per FMI, the soy protein segment is forecast to account for over 80% of the market through 2031.

Key Takeaways from the Texturized Vegetable Protein Market Study

The North American texturized vegetable protein market leads in terms of market size and accounts for 30.1% of the global texturized vegetable protein market in 2021. The Soy Protein texturized vegetable protein market is expected to have a market share of 70.0% of the global texturized vegetable protein market in 2031. In the nature segment, Conventional holds 97.9 % of the texturized vegetable protein market.

In the end-user segment, Industry holds the maximum market share of 76.1% in 2021 of texturized vegetable protein market where Meat Analogues holds 42.8% globally in 2021. Soy protein has a major share by product type and is anticipated to grow significantly over the forecast period. North America have a large number of companies and thus, majority of companies are emphasizing on offering non-GMO products, which are processed through extrusion-based technology, with enhanced functional properties so that their product can comply with strict requirements of clean label products.

“Benefits of opting vegan proteins are now gaining popularity due to which many big companies are investing in the production and innovation of texturized vegetable protein. Several manufacturers are acquiring or merging with key companies to expand their product portfolio and increase their market share. E-commerce and online stores are easing entry barriers and distribution costs. These factors are expected to make competition fiercer within the market” said a lead analyst at FMI

Who is Winning?

The global population is increasing at a rapid rate and it is expected that the population will be around 9.5 Bn by 2050 from 7 Bn in 2017. The situation is set to put quite a strain on the food and supply of raw material, resulting in the need for alternate protein sources. Key players operating in the market are adopting various strategies, which include expansion of production capacity and launch of various products.

A few of the leading players operating in the texturized vegetable protein market are Archer Daniels Midland Company, CHS Inc., Roquette Frères, Beneo GmbH, Danisco A/S, Vestkron A/S, Cargill Inc., FUJI OIL CO., LTD., Puris Proteins, LLC., MGP Ingredients, Inc., Crown Soya Protein Group, Sotexpro SA, Wilmar International Ltd., Gushen Biotechnology Group Co., Ltd., Ingredion Inc.

Don’t Miss Out on the Report, Buy Now: https://www.futuremarketinsights.com/checkout/2747

Texturized Vegetable Protein Market Key Segments

Product Type

Soy Protein
Wheat Protein
Pea Protein
Rice Protein

Nature

Organic
Conventional

Form

Chunks
Slice
Flakes
Granules

End Users

Household
Commercial
Industry
- Food Industry
  - Bakery
  - Snacks
  - Ready Meals
  - Sports Nutrition
  - Clinical Nutrition
  - Baby Food
  - Meat Analogues
  - Others
- Animal Feed

Distribution Channel

Direct
Indirect
- Store Based
- Hypermarket
- Convenience St.
- Traditional Store
- Online Retails

Region

North America
Latin America
Europe
East Asia
South Asia
Middle East and Africa (MEA)
Oceania

About Future Market Insights, Inc.

Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse Other Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs

Aquaponics Market Projected to Exceed USD 3,415.5 Million by 2033, Finds Future Market Insights Inc.

The global aquaponics market is anticipated to rise significantly, rising from US$ 1,560 million in 2023 to US$ 3,415.5 million by 2033, per FMI study. Aquaponics, a sustainable farming technique that combines aquaculture and hydroponics, has a number of advantages over traditional crop cultivation, including significant water savings and a decreased need for pesticides and synthetic fertilisers due to effective resource management.

As per FMI’s analysis, the global aquaponics market is predicted to surge from US$ 1,560 million in 2023 to US$ 3,415.5 Million by 2033. The aquaponics industry is set to observe significant growth in the assessment period. Aquaponics proponents frequently quote plenty of advantages that result from this form of farming.

It has a lot going for it, including environmental awareness. Only 10% of the water required for conventional crop cultivation is used in aquaponics systems. The usage of pesticides, herbicides, and synthetic fertilisers can be drastically decreased or perhaps totally eliminated with effective resource management.

Due to the growing global warming, consumers are undoubtedly being more careful when making daily decisions. As a result, people all across the world are getting pickier and more interested in sustainable practises.

The aquaponics systems can be readily scaled to suit market demands if there is enough room. Producers and farmers are in a stronger position as a result. Business prospects are expected to rise as a result of all of the aforementioned advantages in the years to come.

However, a few restrictions associated to aquaponics could prevent the growth of the sector. Most people would classify aquaponics as a labour- and management-intensive discipline. This is due to ongoing research on fish health, water quality, and plant infections.

Aside from this, controlling temperature can be expensive and time-consuming. This is particularly true when operations last all year long and into the winter. Costly system components can be either built or purchased. In the aquaponics system, some fish species can be difficult to grow to market size. Additionally, toxicity problems and delayed harvests might result from the treatment of pests and diseases.

These are just a few of the difficulties that farmers and connected businesses must overcome. It is anticipated that a wide range of opportunities for aquaponics would spur market expansion.

Top Highlights from the FMI’s Analysis of the Aquaponics Market:

The United States market is projected to attain a lion’s share over the forecast period. The country has been estimated for a 26.8% market share in 2022.
In Europe, Germany grabbed a 5.5% market share. Alongside this, the United Kingdom is projected to register a CAGR of 5.1%.
The intensely growing market for aquaponics is assessed to be India in the forecast period. The country is anticipated to assume a pace of 16% CAGR.
Based on application, the fish segment is projected to be at the forefront.
Based on application, fruits, and vegetables are expected to be the top segments in the coming years.

Competitive Landscape of Aquaponics Market: A Closer Look at Market Whereabouts:

Key players in the market are working on promotional activities to capture users at a wider scale and increase their revenue. Manufacturers are also providing and practising quality certifications to raise their market presence. This also creates awareness among people and unfolds substantial opportunities for key companies.

Presently, Nelson & Pade Aquaponics provides a patented Clear Flow Aquaponics System, equipped with ZDEP from Nelson Pade. These are fully-developed comprehensive system packages that are suitable for those planning to produce aquaponics food on a substantial scale.

Take advantage of this opportunity to buy now and contribute to the sustainable farming of the future: https://www.futuremarketinsights.com/checkout/4376

Key Companies Profiled:

Nelson & Pade Aquaponics, Practical Aquaponics, Aquaponics USA, The Aquaponic Source, Pentair Aquatic Eco-System, Inc.

Key Segments

By Type:

Media Filled Grow Beds (MFG)
Nutrient Film Technique (NFT)
Deep Water Culture (DWC)
Others

By Component:

Bio Filter
Settling Basins
Fish tanks
Soil-free plant bed
Rearing Tanks
Aquaponics Produce
Others

By Equipment:

Pumps and Valves
Water Heaters
Fish Purge Systems
Aeration Systems
Water Quality Testing
Others

By Applications:

Fish
Herbs
Fruits
Vegetables

By End User:

Commercial
Home Production
Research

By Regions:

North America
Latin America
Europe
East Asia
South Asia
Oceania
Middle East & Africa

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Macadamia Industry Set to Reach USD 5.2 Billion by 2034 as Healthy Snacking Gains Popularity

The global macadamia market size is valued at USD 2.45 billion in 2024 and is anticipated to surpass a valuation of USD 5.2 billion by 2034. The macadamia market expansion is estimated at a CAGR of 7.80% from 2024 to 2034.

People are becoming more cognizant of their health and realizing how important it is to choose wholesome snack alternatives. Macadamia nuts are unique because they contain a high percentage of monounsaturated fat, which is associated with heart health benefits. Snacks that not only satiate appetites but also improve consumers’ well-being are highly sought after. The demand for macadamia nuts as a guilt-free snack option has increased due to this trend toward better eating habits, which is fueling the market’s rise.

Culinary trends and shifting customer tastes are the primary causes of the food industry’s ongoing change. The distinct flavor and texture of macadamia nuts present an opportunity for culinary innovators and food producers to develop novel products. Macadamia nuts lend a sense of richness and refinement to a variety of culinary products, from rich chocolates to healthful salads. The increasing need for high-quality ingredients is mirrored in the demand for macadamia nuts, which are a flexible and aromatic addition to a wide range of food items.

Hawaii, South Africa, Australia, and other places with suitable weather are the places where macadamia nuts are grown. These regions have realized how profitable it is to ship macadamia nuts abroad, particularly to nations where they are not customarily eaten. With their expanding middle classes and rising disposable incomes, emerging countries like China and India offer substantial prospects for market development. Producers can widen their client base and encourage future growth in the worldwide macadamia industry by utilizing these export destinations.

Key Takeaways from the Macadamia Market Report

The global market size expanded at a 6.60% CAGR from 2019 to 2023.
The organic nature segment holds 21% of market shares in 2024.
The raw form segment captured 24% of market shares in 2024.
The market size in the United States is projected to rise at a 6.60% CAGR through 2034.
The market size in Germany is anticipated to develop at a 7.60% CAGR through 2034.
The market size in China is estimated to surge at a 3.40% CAGR through 2034.
The market size in India is expected to increase at a 4.20% CAGR through 2034.

Competitive Landscape

The macadamia market is competitive, with established competitors and rising rivals fighting for market dominance and distinction. Established firms, such as Mauna Loa Macadamia Nut Corporation and Macadamia Processing Company (MPC), have strong brand awareness and distribution networks, providing them a competitive advantage in key markets. These companies frequently use economies of scale, vertical integration, and strategic alliances to preserve their market leadership and promote expansion.

Recent Developments

In September 2023, Milkadamia launched two new products, Milkadamia Coffee Latte, and Milkadamia Milk Tea. Both products are made using macadamia milk.
In March 2023, PlantBaby launched organic macadamia milk under its Kiki Milk portfolio.

Note from the Analysts

“Success in the growing macadamia industry requires investing in creativity, cooperation, and sustainability. Companies must concentrate on differentiating themselves and fulfilling sustainability standards in order to succeed in severe competition and shifting consumer preferences.” Says a Lead Analyst at Future Market Insights (FMI).

Get Full Report:
https://www.futuremarketinsights.com/checkout/1304

The Market has been Segmented as

By Nature:

Organic
Conventional

By Form:

Raw
Processed
Oil

By End Use:

Residential
Commercial
Industrial
Food Industry
- Confectionery
- Bakery
- Dairy
- Snacks
- Others
Cosmetic and Personal Care

By Distribution Channel:

Direct
Indirect

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Licorice Root Market Expected to Surpass USD 2 Billion by 2034, Finds FMI Study

The global licorice root market is anticipated to reach a valuation of US$ 980.0 million in 2024, driven by expansion of nutraceutical industry. The trend is expected to create new opportunities for the market, leading to a projected CAGR of 7.4% between 2024 and 2034, and reaching a total valuation of approximately US$ 2,002.1 million by 2034.

Ongoing research and development activities focused on exploring the therapeutic properties and potential applications of licorice root are expanding the market opportunities, which includes studies on its anti-inflammatory, anti-diabetic, and anti-cancer properties, among others.

The increasing demand for functional food and beverages, which offer health benefits beyond basic nutrition, is driving the inclusion of licorice root extracts as a natural ingredient. The trend is expected to continue as consumers seek healthier alternatives to traditional products.

There is an increasing preference for herbal supplements among consumers seeking natural remedies for health issues, with growing concerns about synthetic chemicals and their side effects. Licorice root supplements are witnessing increased demand due to their perceived health benefits and minimal side effects.

The licorice root, being a natural plant extract, is gaining traction as a preferred ingredient in various products catering to vegan and vegetarian consumers, as the global trend towards plant based diets and ingredients continues.

The proliferation of e-commerce platforms has made it easier for consumers to access a wide range of licorice root products globally. The expansion of online retail channels provides manufacturers with greater reach and access to a larger consumer base, thereby augmenting the market growth.

Destinations known for traditional medicine practices, such as Ayurveda retreats in India or wellness spas in Thailand, are witnessing an influx of tourists seeking holistic healing experiences. Licorice root based treatments and products play a significant role in such wellness tourism offerings.

Key Takeaways from the Market Study

Global licorice root market was valued at US$ 703.9 million in 2019.
From 2019 to 2023, the market demand expanded at a CAGR of 6.9%.
The market in Japan is expected to expand at a CAGR of 6.3% through 2034.
By product form, the extracts segment to account for a share of 70.3% in 2024.
The market in India is expected to expand at a CAGR of 7.9% through 2034.
In terms of end use, the tobacco industry segment to account for a revenue share 70.9%.

“Companies are continuously innovating to develop new and unique product formulations containing licorice root extracts. The development includes combinations with other natural ingredients to enhance efficacy or create novel product offerings, catering to evolving consumer preferences,” says Nandini Roy Choudhury (Client Partner for Food & Beverages at Future Market Insights, Inc.).

Competitive Landscape

Prominent players in the licorice root market are FC Licorice, Norevo GmbH, Zagros Licorice Co., Naturex SA, Sepidan Osareh Co., VPL Chemicals, MAFCO Worldwide LLC, and Aseh Co., among others.

Company Portfolio

Maruzen Pharmaceuticals Co. Ltd., based in Japan, is a key player in the licorice root market, particularly in the pharmaceutical and herbal medicine sectors. The company focuses on producing standardized licorice root extracts for medicinal purposes, adhering to strict quality standards and regulatory requirements.
Alfarid Corporation Limited, based in Pakistan, is a major supplier of licorice root extracts to the global market. The company specializes in licorice root cultivation, processing, and export, offering a diverse range of licorice products tailored to customer specifications and industry requirements.

Gain Immediate Access to Detailed Market Insights Purchase Now: https://www.futuremarketinsights.com/checkout/3135

More Valuable Insights Available

Future Market Insights offers an unbiased analysis of the global licorice root market, providing historical data for 2019 to 2023 and forecast statistics from 2024 to 2034.

To understand opportunities in the licorice root market, the market is segmented on the basis of product form (roots, extracts), and end use (food and beverage industry, tobacco industry, pharmaceutical industry, cosmetic industry, dietary supplements), across seven major regions (North America, Latin America, Western Europe, Eastern Europe, South Asia & Pacific, East Asia, and Middle East & Africa (MEA)).

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube